Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL543358 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3259892 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| SCHEMBL218263 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| SCHEMBL540214 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| SCHEMBL218262 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL27745869 | 0.89 | SLC15A1 (0.46) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2916431 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28349108 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27309456 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27309455 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2AIDO1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | MEDIBEACON INC. (US) | 2025-06-03 | — | — | US | claimed |
| EP-4313172-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | Medibeacon Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117241839-A | Preparation of substituted diaminopyrazine dicarboxylic acids | 麦迪贝肯有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20220324818-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. | 2022-10-13 | — | — | US | claimed |
| WO-2022212077-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4019528-B1 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | SHENZHEN YUNHE PHARMACEUTICAL TECH PARTNERSHIP LIMITED (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | SHENZHEN YUNHE PHARMACEUTICAL TECHNOLOGY PARTNERSHIP (LIMITED) (CN) | 2025-12-09 | — | — | US | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | MEDIBEACON INC. (US) | 2025-06-03 | — | — | US | disclosed |
| CN-114555087-B | Anodic oxidation of 5-aminouracil | 麦迪贝肯有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025055882-A1 | MB-102 RELATED COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-117769543-A | Method for preparing pyrazine carboxylic acid derivatives as fluorescent tracers | 杭州中美华东制药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-6124298-A | USED IN REGULATING HAEMATOPOIESIS | NYCOMED IMAGING AS (NO) | 2000-09-26 | — | — | US | disclosed |
| EP-0799208-B1 | PYRIDINE AND PYRAZINEDICARBOXYLIC-ACID DERIVATIVES AS CELL PROLIFERATION REGULATORS | NYCOMED IMAGING AS (NO) | 2000-09-13 | — | — | EP | disclosed |
| US-5972926-A | REACTING A DIAMINE DERIVATIVE WITH PYRIDINE OR PYRIZINE 2,3-DICARBOXYLIC ACID OR 2,3-CARBOXYLIC ANHYDRIDE, CONVERTING THE COMPOUND INTO A SALT, RESOLVING THE FORMED COMPOUND INTO ITS ISOMER | NYCOMED IMAGING AS (NO) | 1999-10-26 | — | — | US | disclosed |
| US-5925659-A | SUBSTITUTED 4-HYDROXAMIDO-2-PHENYL-OXAZOLINES FOR TREATMENT OF GRAMNEGATIVE BACTERIAL INFECTIONS | MERCK & CO., INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5693772-A | PROTECTING ACID AND HYDROXY GROUPS OF BENANOMICIN A, REDUCTION OF AMIDE TO IMIDOESTER WITH MEERWEIN REAGENT, DEPROTECTING, REFLUXING IN ACETONE/WATER MIXTURE TO CLEAVE IMIDOESTER AND FORM CARBOXY GROUP | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1997-12-02 | — | — | US | disclosed |
| EP-0799208-A1 | PYRIDINE AND PYRAZINEDICARBOXYLIC-ACID DERIVATIVES AS CELL PROLIFERATION REGULATORS | NYCOMED IMAGING AS (NO) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019457-A1 | PYRIDINE AND PYRAZINEDICARBOXYLIC-ACID DERIVATIVES AS CELL PROLIFERATION REGULATORS | NYCOMED IMAGING AS (NO) | 1996-06-27 | — | — | WO | disclosed |
| EP-0684253-A1 | DESALANINEBENANOMICIN A DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319660-B2 | Preparation of substituted diaminopyrazine dicarboxylic acids | DDC, DPYD, SDHA | SLC6A2 992/4885SLC6A3 1571/4885PTGS1 2708/4885 |
| US-20220324818-A1 | PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | DDC, DPYD, SDHA | SLC6A2 992/4885SLC6A3 1571/4885PTGS1 2708/4885 |
| US-12491190-B2 | Bile acid derivative, composition and application thereof | NR1H4, GPBAR1, GLP1R | SLC6A2 2725/4885SLC6A3 2691/4885PTGS1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.